Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711932 · ClinicalTrials.gov registry record
The Effect of TRA-8 on Ovarian Cancer Tissue
A clinical trial of Ovarian Cancer, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 478
- Enrollment target
- 1
- Study location
NCT00711932 is a study of Ovarian Cancer that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 478 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00711932, a study of Ovarian Cancer, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 478 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology. In addition, we want to evaluate the expression of apoptosis regulatory proteins using multiplex proteomic technology and its correlation with TRA-8-induced cytotoxicity in patient ovarian cancer tissues.
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711932
The ClinicalTrials.gov registry entry for NCT00711932 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (34% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00711932 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00711932 about?
NCT00711932 is a clinical study titled "The Effect of TRA-8 on Ovarian Cancer Tissue". The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology. In addition, we want to evaluate the expression of apoptosis regulatory proteins using multiplex proteomic technology and its correlation with TRA-8-indu...
What is the current status of trial NCT00711932?
This trial is currently completed. The enrollment target is 478 participants. The study started on 2008-08. Estimated completion is 2013-01.
What conditions does trial NCT00711932 study?
This clinical trial studies the following conditions: Ovarian Cancer.
Who is sponsoring clinical trial NCT00711932?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00711932 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.